Smoking Cessation Pharmacotherapy

Smoking cessation pharmacotherapy is the use of medications to help people stop smoking by easing nicotine withdrawal and craving. The main evidence-based options are nicotine replacement therapy, the nicotinic partial agonist varenicline, and the atypical antidepressant bupropion, used alongside behavioural support.

Definition

Smoking cessation pharmacotherapy is the use of nicotine replacement therapy, varenicline, or bupropion, combined with behavioural support, to relieve nicotine withdrawal and craving and increase the likelihood of sustained abstinence from tobacco.

Scope

This topic covers the three first-line medication strategies for tobacco use disorder, their mechanisms, and the network meta-analytic evidence comparing them. It is a reference entry within addiction pharmacotherapy and does not provide dosing or prescribing instructions.

Core questions

• How do nicotine replacement, varenicline, and bupropion differ in mechanism?
• What does network meta-analysis show about their comparative efficacy?
• Why is behavioural support combined with pharmacotherapy?
• How does nicotine dependence fit the broader model of substance use disorders?

Key concepts

• Tobacco/nicotine use disorder
• Nicotine replacement therapy (NRT)
• Varenicline (nicotinic partial agonist)
• Bupropion
• Nicotinic acetylcholine receptor
• Withdrawal and craving relief
• Combined pharmacological and behavioural support

Mechanisms

The medications act on nicotine's target, the nicotinic acetylcholine receptor, by different routes. Nicotine replacement therapy delivers controlled doses of nicotine without tobacco smoke, reducing withdrawal and craving while the smoker breaks the behavioural habit. Varenicline is a partial agonist at the alpha-4-beta-2 nicotinic receptor: it relieves withdrawal by partially stimulating the receptor while blunting the reward of smoking by occupying the receptor. Bupropion, an atypical antidepressant, reduces craving through dopaminergic and noradrenergic effects and antagonism of nicotinic receptors. Cochrane reviews by Cahill and colleagues, including a network meta-analysis, summarize the comparative evidence and identify varenicline as among the most effective single agents.

Clinical relevance

Pharmacotherapy substantially increases the chance of quitting smoking and is a core element of tobacco use disorder management; understanding the options supports informed reading of the cessation literature. This entry is descriptive and educational and does not provide individualized treatment or dosing recommendations, which follow current guidelines.

Epidemiology

Tobacco use is a leading preventable cause of death worldwide, and most smokers who try to quit without assistance relapse. Effective cessation medications can roughly increase quit rates compared with placebo, yet remain underused relative to the size of the smoking population.

Evidence & guidelines

Cochrane systematic reviews and network meta-analysis support nicotine replacement therapy, varenicline, and bupropion as first-line pharmacotherapies, with varenicline and combination nicotine replacement among the most effective; guidelines recommend pairing medication with behavioural support. DSM-5 frames tobacco use disorder diagnostically.

History

Nicotine replacement therapy, introduced in the 1980s as nicotine gum and later patches, was the first dedicated smoking-cessation pharmacotherapy. Bupropion was subsequently found to aid cessation, and varenicline, designed specifically as a nicotinic partial agonist, was approved in the mid-2000s and became a leading single-agent treatment, reflecting an increasingly receptor-targeted approach to nicotine dependence.

Debates

Comparative efficacy and safety of first-line agents

Network meta-analysis indicates varenicline and combination nicotine replacement are among the most effective options, but the relative ranking of agents and historical safety concerns about specific medications have been the subject of ongoing evaluation.

Key figures

• Kate Cahill
• Tim Lancaster
• Nora Volkow

Seminal works

• cahill-2013
• cahill-2016

Frequently asked questions

What are the main medications for quitting smoking?

The first-line options are nicotine replacement therapy (such as patches and gum), varenicline (a nicotinic partial agonist), and bupropion (an atypical antidepressant), all of which increase quit rates compared with placebo when combined with behavioural support.

Is medication enough on its own to quit smoking?

Pharmacotherapy improves quit rates but works best when combined with behavioural support; medication eases withdrawal and craving while behavioural support helps change the smoking habit itself.